Hengrui Pharmaceutical (600276.SH): HRS-4729 injection approved for clinical trials

Zhitongcaijing · 09/04/2025 09:49

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration (“State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for HRS-4729 injections and will conduct clinical trials in the near future.

HRS-4729 injection is a polypeptide drug independently developed by the company. It is a glucagon-like peptide-1 receptor (GLP-1R) /glucose-dependent insulin-stimulating polypeptide receptor (GIPR) /glucagon receptor (GCGR) triple agonist. Compared with GLP-1R/GIPR dual targets, triple receptor agonists increase GCGR target activation activity on the basis of regulating carbohydrate metabolism and suppressing appetite in the body, and promote energy consumption, fatty acid oxidation, and lipid breakdown, thereby better exhibiting the effects of weight loss and liver fat reduction.